ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)

Clinical Microbiology and Infection

Volumn 24, Issue , 2018, Pages S10-S20

  Baddley, J W ^a   Cantini, F ^b   Goletti, D ^c   Gomez Reino J J ^d   Mylonakis, E ^e   San Juan, R ^f,h   Fernandez Ruiz M ^f,h   Torre Cisneros, J ^g,h  

^a University of Alabama at Birmingham   (United States)

^b Hospital of Prato   (Italy)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e BROWN UNIVERSITY   (United States)

^f Universidad Complutense   (Spain)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^h INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Adalimumab; Certolizumab pegol; Etanercept; Golimumab; Infection; Infliximab; Prevention; Tuberculosis; Tumour necrosis factor

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; LIVE VACCINE; ANTIINFLAMMATORY AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR; VIRUS VACCINE;

BACTERIAL INFECTION; BIOLOGICAL THERAPY; CLINICAL STUDY; DRUG MECHANISM; DRUG SAFETY; GRANULOMATOSIS; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION; INFECTION RISK; LATENT TUBERCULOSIS; MYCOSIS; NONHUMAN; OFF LABEL DRUG USE; PNEUMOCYSTIS; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; VIRUS INFECTION; ANTAGONISTS AND INHIBITORS; CHRONIC HEPATITIS B; CLINICAL TRIAL (TOPIC); COMMUNICABLE DISEASE; COMMUNICABLE DISEASE CONTROL; CONSENSUS DEVELOPMENT; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ADALIMUMAB; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; CLINICAL TRIALS AS TOPIC; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; ETANERCEPT; HEPATITIS B, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC FACTORS; INFLIXIMAB; LATENT TUBERCULOSIS; MOLECULAR TARGETED THERAPY; TUMOR NECROSIS FACTOR-ALPHA; VIRAL VACCINES;

EID: 85042098941     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2017.12.025     Document Type: Review

References (146)

1. Fernández-Ruiz, M., Meije, Y., Manuel, O., Akan, H., Carratalà J., Aguado, J.M., et al. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (introduction). Clin Microbiol Infect 24 (2018), S2–S9.
2. Black, R.A., Rauch, C.T., Kozlosky, C.J., Peschon, J.J., Slack, J.L., Wolfson, M.F., et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 385 (1997), 729–733.
3. Billmeier, U., Dieterich, W., Neurath, M.F., Atreya, R., Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol 22 (2016), 9300–9313.
4. Ungar, B., Kopylov, U., Advances in the development of new biologics in inflammatory bowel disease. Ann Gastroenterol 29 (2016), 243–248.
5. Chaabo, K., Kirkham, B., Rheumatoid arthritis—anti-TNF. Int Immunopharmacol 27 (2015), 180–184.
6. Yamanaka, H., TNF as a target of inflammation in rheumatoid arthritis. Endocr Metab Immune Disord Drug Targets 15 (2015), 129–134.
7. Elyoussfi, S., Thomas, B.J., Ciurtin, C., Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies. Rheumatol Int 36 (2016), 603–612.
8. Yamauchi, P.S., Bissonnette, R., Teixeira, H.D., Valdecantos, W.C., Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent. J Am Acad Dermatol, 75, 2016 612–618.e6.
9. Siddiqui, M.A., Scott, L.J., Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Drugs 65 (2005), 2179–2208.
10. Robinson, D.M., Keating, G.M., Infliximab: in ankylosing spondylitis. Drugs 65 (2005), 1283–1291 discussion 92–4.
11. Veres, G., Baldassano, R.N., Mamula, P., Infliximab therapy in children and adolescents with inflammatory bowel disease. Drugs 67 (2007), 1703–1723.
12. Burness, C.B., McKeage, K., Adalimumab: a review in chronic plaque psoriasis. Drugs 75 (2015), 2119–2130.
13. Burness, C.B., Deeks, E.D., Adalimumab: in non-radiographic axial spondyloarthritis. Drugs 72 (2012), 2385–2395.
14. Tanaka, Y., Senoo, A., Fujii, H., Baker, D., Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis. Expert Opin Drug Metab Toxicol 12 (2016), 319–326.
15. Ueda, N., Tsukamoto, H., Mitoma, H., Ayano, M., Tanaka, A., Ohta, S., et al. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α. Inflamm Bowel Dis 19 (2013), 1224–1231.
16. Capogrosso Sansone, A., Mantarro, S., Tuccori, M., Ruggiero, E., Montagnani, S., Convertino, I., et al. Safety profile of certolizumab pegol in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis. Drug Saf 38 (2015), 869–888.
17. Ali, T., Kaitha, S., Mahmood, S., Ftesi, A., Stone, J., Bronze, M.S., Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf 5 (2013), 79–99.
18. Koo, S., Marty, F.M., Baden, L.R., Infectious complications associated with immunomodulating biologic agents. Hematol Oncol Clin North Am 25 (2011), 117–138.
19. Roach, D.R., Bean, A.G., Demangel, C., France, M.P., Briscoe, H., Britton, W.J., TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168 (2002), 4620–4627.
20. Tracey, D., Klareskog, L., Sasso, E.H., Salfeld, J.G., Tak, P.P., Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117 (2008), 244–279.
21. Wallis, R.S., Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 8 (2008), 601–611.
22. Scallon, B., Cai, A., Solowski, N., Rosenberg, A., Song, X.Y., Shealy, D., et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301 (2002), 418–426.
23. MacEwan, D.J., TNF ligands and receptors—a matter of life and death. Br J Pharmacol 135 (2002), 855–875.
24. Cantini, F., Niccoli, L., Goletti, D., Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries. J Rheumatol Suppl 91 (2014), 56–64.
25. Singh, J.A., Wells, G.A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L., Macdonald, J.K., et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev, 2011, CD008794.
26. Singh, J.A., Cameron, C., Noorbaloochi, S., Cullis, T., Tucker, M., Christensen, R., et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 386 (2015), 258–265.
27. Minozzi, S., Bonovas, S., Lytras, T., Pecoraro, V., Gonzalez-Lorenzo, M., Bastiampillai, A.J., et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf 15 (2016), 11–34.
28. Ai, J.W., Zhang, S., Ruan, Q.L., Yu, Y.Q., Zhang, B.Y., Liu, Q.H., et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-α antagonist: a metaanalysis of both randomized controlled trials and registry/cohort studies. J Rheumatol 42 (2015), 2229–2237.
29. Souto, A., Maneiro, J.R., Salgado, E., Carmona, L., Gomez-Reino, J.J., Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford) 53 (2014), 1872–1885.
30. Gomez-Reino, J.J., Carmona, L., Valverde, V.R., Mola, E.M., Montero, M.D., Group, B., Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48 (2003), 2122–2127.
31. Askling, J., Fored, C.M., Brandt, L., Baecklund, E., Bertilsson, L., Coster, L., et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52 (2005), 1986–1992.
32. Listing, J., Strangfeld, A., Kary, S., Rau, R., von Hinueber, U., Stoyanova-Scholz, M., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52 (2005), 3403–3412.
33. Brassard, P., Kezouh, A., Suissa, S., Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 43 (2006), 717–722.
34. Gomez-Reino, J.J., Carmona, L., Angel Descalzo, M., Biobadaser, G., Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57 (2007), 756–761.
35. Favalli, E.G., Desiati, F., Atzeni, F., Sarzi-Puttini, P., Caporali, R., Pallavicini, F.B., et al. Serious infections during anti-TNFα treatment in rheumatoid arthritis patients. Autoimmun Rev 8 (2009), 266–273.
36. Tubach, F., Salmon, D., Ravaud, P., Allanore, Y., Goupille, P., Breban, M., et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60 (2009), 1884–1894.
37. Dixon, W.G., Hyrich, K.L., Watson, K.D., Lunt, M., Galloway, J., Ustianowski, A., et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69 (2010), 522–528.
38. Atzeni, F., Sarzi-Puttini, P., Botsios, C., Carletto, A., Cipriani, P., Favalli, E.G., et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 12 (2012), 225–229.
39. Winthrop, K.L., Baxter, R., Liu, L., Varley, C.D., Curtis, J.R., Baddley, J.W., et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 72 (2013), 37–42.
40. Takeuchi, T., Tatsuki, Y., Nogami, Y., Ishiguro, N., Tanaka, Y., Yamanaka, H., et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67 (2008), 189–194.
41. Koike, T., Harigai, M., Inokuma, S., Inoue, K., Ishiguro, N., Ryu, J., et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 36 (2009), 898–906.
42. Koike, T., Harigai, M., Ishiguro, N., Inokuma, S., Takei, S., Takeuchi, T., et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol 22 (2012), 498–508.
43. Kim, E.M., Uhm, W.S., Bae, S.C., Yoo, D.H., Kim, T.H., Incidence of tuberculosis among Korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers. J Rheumatol 38 (2011), 2218–2223.
44. Alawneh, K.M., Ayesh, M.H., Khassawneh, B.Y., Saadeh, S.S., Smadi, M., Bashaireh, K., Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis. Biologics 8 (2014), 193–198.
45. Kisacik, B., Pamuk, O.N., Onat, A.M., Erer, S.B., Hatemi, G., Ozguler, Y., et al. Characteristics predicting tuberculosis risk under tumor necrosis factor-α inhibitors: report from a large multicenter cohort with high background prevalence. J Rheumatol 43 (2016), 524–529.
46. Keane, J., Gershon, S., Wise, R.P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 345 (2001), 1098–1104.
47. Cantini, F., Nannini, C., Niccoli, L., Iannone, F., Delogu, G., Garlaschi, G., et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev 14 (2015), 503–509.
48. Lobue, P., Menzies, D., Treatment of latent tuberculosis infection: an update. Respirology 15 (2010), 603–622.
49. Jensen, P.A., Lambert, L.A., Iademarco, M.F., Ridzon, R., CDC, Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings. MMWR Recomm Rep 2005:54 (2005), 1–141.
50. Brassard, P., Lowe, A.M., Bernatsky, S., Kezouh, A., Suissa, S., Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum 61 (2009), 300–304.
51. Jick, S.S., Lieberman, E.S., Rahman, M.U., Choi, H.K., Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 55 (2006), 19–26.
52. Ford, A.C., Peyrin-Biroulet, L., Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 108 (2013), 1268–1276.
53. Osterman, M.T., Sandborn, W.J., Colombel, J.F., Peyrin-Biroulet, L., Robinson, A.M., Zhou, Q., et al. Crohn's disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab. Am J Gastroenterol 111 (2016), 1806–1815.
54. Bonovas, S., Fiorino, G., Allocca, M., Lytras, T., Nikolopoulos, G.K., Peyrin-Biroulet, L., et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol, 14, 2016 1385–1397.e10.
55. Santin, M., Garcia-Garcia, J.M., Dominguez, J., Panel of experts from the Mycobacteria Study Group of the Spanish Society of Infectious D, Clinical M, the Spanish Society of Respiratory D. Guidelines for the use of interferon-γ release assays in the diagnosis of tuberculosis infection. Enferm Infecc Microbiol Clin, 34, 2016 303 e1–13.
56. Munoz, L., Casas, S., Juanola, X., Bordas, X., Martinez, C., Santin, M., et al. Prevention of anti-tumor necrosis factor-associated tuberculosis: a 10-year longitudinal cohort study. Clin Infect Dis 60 (2015), 349–356.
57. Singh, J.A., Furst, D.E., Bharat, A., Curtis, J.R., Kavanaugh, A.F., Kremer, J.M., et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64 (2012), 625–639.
58. Hatzara, C., Hadziyannis, E., Kandili, A., Koutsianas, C., Makris, A., Georgiopoulos, G., et al. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases. Ann Rheum Dis 74 (2015), 1848–1853.
59. Michaud, T.L., Rho, Y.H., Shamliyan, T., Kuntz, K.M., Choi, H.K., The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. Am J Med 127 (2014), 1208–1232.
60. Fouque-Aubert, A., Jette-Paulin, L., Combescure, C., Basch, A., Tebib, J., Gossec, L., Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis 69 (2010), 1756–1761.
61. Dommasch, E.D., Abuabara, K., Shin, D.B., Nguyen, J., Troxel, A.B., Gelfand, J.M., The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 64 (2011), 1035–1050.
62. Zhang, D., Xiong, B., Li, X., Xu, T., Yu, M., Meta-analysis: serious adverse events in Crohn's disease patients treated with TNF-α inhibitors. Hepatogastroenterology 60 (2013), 1333–1342.
63. Strangfeld, A., Eveslage, M., Schneider, M., Bergerhausen, H.J., Klopsch, T., Zink, A., et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?. Ann Rheum Dis 70 (2011), 1914–1920.
64. Grijalva, C.G., Chen, L., Delzell, E., Baddley, J.W., Beukelman, T., Winthrop, K.L., et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 306 (2011), 2331–2339.
65. Galloway, J.B., Hyrich, K.L., Mercer, L.K., Dixon, W.G., Fu, B., Ustianowski, A.P., et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50 (2011), 124–131.
66. Askling, J., Dixon, W., The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 20 (2008), 138–144.
67. Askling, J., Fored, C.M., Brandt, L., Baecklund, E., Bertilsson, L., Feltelius, N., et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 66 (2007), 1339–1344.
68. Dixon, W.G., Symmons, D.P., Lunt, M., Watson, K.D., Hyrich, K.L., British Society for Rheumatology Biologics Register Control Centre C. Serious infection following anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 56 (2007), 2896–2904.
69. Au, K., Reed, G., Curtis, J.R., Kremer, J.M., Greenberg, J.D., Strand, V., et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 70 (2011), 785–791.
70. Emery, P., Gallo, G., Boyd, H., Morgan, C.L., Currie, C.J., Poole, C.D., et al. Association between disease activity and risk of serious infections in subjects with rheumatoid arthritis treated with etanercept or disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol 32 (2014), 653–660.
71. Novosad, S.A., Winthrop, K.L., Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae. Clin Infect Dis 58 (2014), 1587–1598.
72. Dixon, W., Felson, D.T., Is anti-TNF therapy safer than previously thought?. JAMA 306 (2011), 2380–2381.
73. Dixon, W.G., Watson, K., Lunt, M., Hyrich, K.L., Silman, A.J., Symmons, D.P., et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54 (2006), 2368–2376.
74. van Dartel, S.A., Fransen, J., Kievit, W., Flendrie, M., den Broeder, A.A., Visser, H., et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 72 (2013), 895–900.
75. Yun, H., Xie, F., Delzell, E., Chen, L., Levitan, E.B., Lewis, J.D., et al. Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. Ann Rheum Dis 74 (2015), 1065–1071.
76. Wallis, D., Thavaneswaran, A., Haroon, N., Ayearst, R., Inman, R.D., Tumour necrosis factor inhibitor therapy and infection risk in axial spondyloarthritis: results from a longitudinal observational cohort. Rheumatology (Oxford) 54 (2015), 152–156.
77. Haddad, A., Li, S., Thavaneswaran, A., Cook, R.J., Chandran, V., Gladman, D.D., The incidence and predictors of infection in psoriasis and psoriatic arthritis: results from longitudinal observational cohorts. J Rheumatol 43 (2016), 362–366.
78. Syed, A., Cross, R.K., Flasar, M.H., Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn's disease patients. Am J Gastroenterol 108 (2013), 583–593.
79. Serradori, T., Germain, A., Scherrer, M.L., Ayav, C., Perez, M., Romain, B., et al. The effect of immune therapy on surgical site infection following Crohn's Disease resection. Br J Surg 100 (2013), 1089–1093.
80. Kopylov, U., Ben-Horin, S., Zmora, O., Eliakim, R., Katz, L.H., Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis. Inflamm Bowel Dis 18 (2012), 2404–2413.
81. Billioud, V., Ford, A.C., Tedesco, E.D., Colombel, J.F., Roblin, X., Peyrin-Biroulet, L., Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. J Crohns Colitis 7 (2013), 853–867.
82. Rizzo, G., Armuzzi, A., Pugliese, D., Verbo, A., Papa, A., Mattana, C., et al. Anti-TNF-α therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. Int J Colorectal Dis 26 (2011), 1435–1444.
83. Norgard, B.M., Nielsen, J., Qvist, N., Gradel, K.O., de Muckadell, O.B., Kjeldsen, J., Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with Crohn's disease—a nationwide cohort study. Aliment Pharmacol Ther 37 (2013), 214–224.
84. Colombel, J.F., Loftus, E.V. Jr., Tremaine, W.J., Pemberton, J.H., Wolff, B.G., Young-Fadok, T., et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 99 (2004), 878–883.
85. Canedo, J., Lee, S.H., Pinto, R., Murad-Regadas, S., Rosen, L., Wexner, S.D., Surgical resection in Crohn's disease: is immunosuppressive medication associated with higher postoperative infection rates?. Colorectal Dis 13 (2011), 1294–1298.
86. Waterland, P., Athanasiou, T., Patel, H., Post-operative abdominal complications in Crohn's disease in the biological era: systematic review and meta-analysis. World J Gastrointest Surg 8 (2016), 274–283.
87. Doran, M.F., Crowson, C.S., Pond, G.R., O'Fallon, W.M., Gabriel, S.E., Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46 (2002), 2287–2293.
88. Wolfe, F., Caplan, L., Michaud, K., Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 54 (2006), 628–634.
89. Galloway, J.B., Hyrich, K.L., Mercer, L.K., Dixon, W.G., Ustianowski, A.P., Helbert, M., et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70 (2011), 1810–1814.
90. Wallis, R.S., Broder, M.S., Wong, J.Y., Hanson, M.E., Beenhouwer, D.O., Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38 (2004), 1261–1265.
91. Slifman, N.R., Gershon, S.K., Lee, J.H., Edwards, E.T., Braun, M.M., Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α-neutralizing agents. Arthritis Rheum 48 (2003), 319–324.
92. Kuehn, B.M., Growing list of infections linked to TNF blockers. JAMA, 306, 2011, 1430.
93. Pena-Sagredo, J.L., Hernandez, M.V., Fernandez-Llanio, N., Gimenez-Ubeda, E., Munoz-Fernandez, S., Ortiz, A., et al. Listeria monocytogenes infection in patients with rheumatic diseases on TNF-α antagonist therapy: the Spanish Study Group experience. Clin Exp Rheumatol 26 (2008), 854–859.
94. Lanternier, F., Tubach, F., Ravaud, P., Salmon, D., Dellamonica, P., Bretagne, S., et al. Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study. Chest 144 (2013), 990–998.
95. Winthrop, K.L., Novosad, S.A., Baddley, J.W., Calabrese, L., Chiller, T., Polgreen, P., et al. Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis 74 (2015), 2107–2116.
96. Winthrop, K.L., Baddley, J.W., Chen, L., Liu, L., Grijalva, C.G., Delzell, E., et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 309 (2013), 887–895.
97. Strangfeld, A., Listing, J., Herzer, P., Liebhaber, A., Rockwitz, K., Richter, C., et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. JAMA 301 (2009), 737–744.
98. Galloway, J.B., Mercer, L.K., Moseley, A., Dixon, W.G., Ustianowski, A.P., Helbert, M., et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 72 (2013), 229–234.
99. Serac, G., Tubach, F., Mariette, X., Salmon-Ceron, D., Ravaud, P., Liote, F., et al. Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry. J Invest Dermatol 132 (2012), 726–729.
100. Garcia-Doval, I., Perez-Zafrilla, B., Descalzo, M.A., Rosello, R., Hernandez, M.V., Gomez-Reino, J.J., et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis 69 (2010), 1751–1755.
101. Langan, S.M., Minassian, C., Smeeth, L., Thomas, S.L., Risk of stroke following herpes zoster: a self-controlled case-series study. Clin Infect Dis 58 (2014), 1497–1503.
102. Yawn, B.P., Wollan, P.C., Nagel, M.A., Gilden, D., Risk of stroke and myocardial infarction after herpes zoster in older adults in a US community population. Mayo Clin Proc 91 (2016), 33–44.
103. Calabrese, L.H., Xie, F., Yun, H., Winthrop, K.L., Baddley, J.W., Calabrese, C., et al. Herpes zoster and the risk of stroke in patients with autoimmune diseases. Arthritis Rheumatol 69 (2017), 439–446.
104. Lavagna, A., Bergallo, M., Daperno, M., Sostegni, R., Costa, C., Leto, R., et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis 13 (2007), 896–902.
105. Shale, M.J., Seow, C.H., Coffin, C.S., Kaplan, G.G., Panaccione, R., Ghosh, S., Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 31 (2010), 20–34.
106. Kim, J.J., Simpson, N., Klipfel, N., Debose, R., Barr, N., Laine, L., Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci 55 (2010), 1059–1065.
107. Wendling, D., Auge, B., Bettinger, D., Lohse, A., Le Huede, G., Bresson-Hadni, S., et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 64 (2005), 788–789.
108. Ueno, Y., Tanaka, S., Shimamoto, M., Miyanaka, Y., Hiyama, T., Ito, M., et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 50 (2005), 163–166.
109. Ostuni, P., Botsios, C., Punzi, L., Sfriso, P., Todesco, S., Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 62 (2003), 686–687.
110. Michel, M., Duvoux, C., Hezode, C., Cherqui, D., Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 30 (2003), 1624–1625.
111. Esteve, M., Saro, C., Gonzalez-Huix, F., Suarez, F., Forne, M., Viver, J.M., Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 53 (2004), 1363–1365.
112. Vassilopoulos, D., Calabrese, L.H., Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol 8 (2012), 348–357.
113. Winthrop, K.L., Calabrese, L.H., Let the fog be lifted: screening for hepatitis B virus before biological therapy. Ann Rheum Dis 70 (2011), 1701–1703.
114. Zein, N.N., Etanercept Study, G., Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 42 (2005), 315–322.
115. Oniankitan, O., Duvoux, C., Challine, D., Mallat, A., Chevalier, X., Pawlotsky, J.M., et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 31 (2004), 107–109.
116. Magliocco, M.A., Gottlieb, A.B., Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 51 (2004), 580–584.
117. Parke, F.A., Reveille, J.D., Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 51 (2004), 800–804.
118. Peterson, J.R., Hsu, F.C., Simkin, P.A., Wener, M.H., Effect of tumour necrosis factor α antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 62 (2003), 1078–1082.
119. Burton, M.J., Curtis, J.R., Yang, S., Chen, L., Singh, J.A., Mikuls, T.R., et al. Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis C virus infection. J Rheumatol, 2017, 565–570.
120. Brunasso, A.M., Puntoni, M., Gulia, A., Massone, C., Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford) 50 (2011), 1700–1711.
121. Salmon-Ceron, D., Tubach, F., Lortholary, O., Chosidow, O., Bretagne, S., Nicolas, N., et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 70 (2011), 616–623.
122. Torre-Cisneros, J., Del Castillo, M., Caston, J.J., Castro, M.C., Perez, V., Collantes, E., Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis. Rheumatology (Oxford) 44 (2005), 1132–1135.
123. Pillet, S., Jarlot, C., Courault, M., Del Tedesco, E., Chardon, R., Saint-Sardos, P., et al. Infliximab does not worsen outcomes during flare-ups associated with cytomegalovirus infection in patients with ulcerative colitis. Inflamm Bowel Dis 21 (2015), 1580–1586.
124. Colaci, M., Sebastiani, M., Sandri, G., Meacci, M., Ferri, C., Epstein–Barr virus reactivation after infliximab in rheumatoid arthritis: a case report. Case Rep Infect Dis, 2011, 2011, 530568.
125. Juan, A., Lobaton, T., Tapia, G., Manosa, M., Cabre, E., Domenech, E., Epstein–Barr virus-positive mucocutaneous ulcer in Crohn's disease. A condition to consider in immunosuppressed IBD patients. Dig Liver Dis 49 (2017), 934–937.
126. Allen, P.B., Laing, G., Connolly, A., O'Neill, C., EBV-associated colonic B-cell lymphoma following treatment with infliximab for IBD: a new problem?. BMJ Case Rep, 2013, 2013.
127. True, D.G., Penmetcha, M., Peckham, S.J., Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab. J Rheumatol 29 (2002), 1561–1563.
128. Hage, C.A., Wood, K.L., Winer-Muram, H.T., Wilson, S.J., Sarosi, G., Knox, K.S., Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-α therapy. Chest 124 (2003), 2395–2397.
129. Wallis, R.S., Broder, M., Wong, J., Lee, A., Hoq, L., Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 41:Suppl. 3 (2005), S194–S198.
130. Hage, C.A., Bowyer, S., Tarvin, S.E., Helper, D., Kleiman, M.B., Wheat, L.J., Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis 50 (2010), 85–92.
131. Bergstrom, L., Yocum, D.E., Ampel, N.M., Villanueva, I., Lisse, J., Gluck, O., et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists. Arthritis Rheum 50 (2004), 1959–1966.
132. Warris, A., Bjorneklett, A., Gaustad, P., Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 344 (2001), 1099–1100.
133. Kaur, N., Mahl, T.C., Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 52 (2007), 1481–1484.
134. Louie, G.H., Wang, Z., Ward, M.M., Trends in hospitalizations for Pneumocystis jiroveci pneumonia among patients with rheumatoid arthritis in the US: 1996-2007. Arthritis Rheum 62 (2010), 3826–3827.
135. Harigai, M., Koike, R., Miyasaka, N., Pneumocystis pneumonia under anti-tumor necrosis factor therapy study G. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 357 (2007), 1874–1876.
136. Komano, Y., Harigai, M., Koike, R., Sugiyama, H., Ogawa, J., Saito, K., et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum 61 (2009), 305–312.
137. Kourbeti, I.S., Ziakas, P.D., Mylonakis, E., Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. Clin Infect Dis 58 (2014), 1649–1657.
138. Goletti, D., Sanduzzi, A., Delogu, G., Performance of the tuberculin skin test and interferon-γ release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches. J Rheumatol Suppl 91 (2014), 24–31.
139. Petruccioli, E., Scriba, T.J., Petrone, L., Hatherill, M., Cirillo, D.M., Joosten, S.A., et al. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. Eur Respir J 48 (2016), 1751–1763.
140. Getahun, H., Matteelli, A., Abubakar, I., Aziz, M.A., Baddeley, A., Barreira, D., et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 46 (2015), 1563–1576.
141. Lewinsohn, D.M., Leonard, M.K., LoBue, P.A., Cohn, D.L., Daley, C.L., Desmond, E., et al. Official American Thoracic society/infectious diseases society of America/Centers for disease control and prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis 64 (2017), 111–115.
142. Koutsianas, C., Thomas, K., Vassilopoulos, D., Hepatitis B reactivation in rheumatic diseases: screening and prevention. Rheum Dis Clin North Am 43 (2017), 133–149.
143. Rubin, L.G., Levin, M.J., Ljungman, P., Davies, E.G., Avery, R., Tomblyn, M., et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58 (2014), 309–318.
144. van Assen, S., Agmon-Levin, N., Elkayam, O., Cervera, R., Doran, M.F., Dougados, M., et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 70 (2011), 414–422.
145. Singh, J.A., Saag, K.G., Bridges, S.L. Jr., Akl, E.A., Bannuru, R.R., Sullivan, M.C., et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68 (2016), 1–26.
146. Bernatsky, S., Habel, Y., Rahme, E., Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists. J Rheumatol 37 (2010), 928–931.